This HTML5 document contains 28 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n8	http://linked.opendata.cz/resource/mesh/concept/
rdfs	http://www.w3.org/2000/01/rdf-schema#
n6	http://linked.opendata.cz/resource/fda-spl/ingredient/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n7	http://linked.opendata.cz/ontology/mesh/
owl	http://www.w3.org/2002/07/owl#
nci	http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
n5	http://linked.opendata.cz/resource/ndfrt/ingredient/
xsdh	http://www.w3.org/2001/XMLSchema#

Statements

Subject Item

nci:C781

rdf:type

owl:Class

rdfs:label

Propylthiouracil

rdfs:subClassOf

nci:C885

nci:A8

nci:C63923

nci:P106

Pharmacologic Substance Nucleic Acid, Nucleoside, or Nucleotide

nci:P108

Propylthiouracil

nci:P175

70461

nci:P207

C0033511

nci:P210

51-52-5

nci:P319

721M9407IY

nci:P322

FDA

nci:P325

<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)</n0:def-definition><n0:def-source>MSH2002_06_01</n0:def-source></n0:ComplexDefinition>

nci:P329

39288

nci:P330

39288

nci:P350

C7H10N2OS

nci:P366

Propylthiouracil

nci:P368

CHEBI:8502

nci:P90

<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>6-Propyl-2-thiouracil</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0070461</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Propylthiouracil</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>6-Propyl-2-Thiouracil</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Propylthiouracil</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0070461</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>PROPYLTHIOURACIL</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>721M9407IY</n0:source-code></n0:ComplexTerm>

nci:P97

<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A thiourea derivative with antithyroid property. Propylthiouracil (PTU) interferes with the oxidation of iodine possibly by interaction with peroxidase or a peroxidase-mediated complex reaction, thereby inhibiting synthesis of thyroid hormones tri-iodothyronine (T3) and thyroxine (T4). In addition, this agent inhibits the Type I 5&#39;-deiodinase (D1), an enzyme involved in the peripheral conversion of thyroxine to tri-iodothyronine. This results in decreased plasma triodothyronine concentrations and decreased entrance of thyroxine into cells thereby reducing thyroid hormone activity.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>

nci:code

C781

owl:sameAs

n5:N0000006787 n6:721M9407IY

n7:hasConcept

n8:M0017784